Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.

Published

Journal Article (Review)

Multiple drug classes have shown incremental benefits in heart failure with reduced ejection fraction. Most of these trials were designed to achieve specific doses of the investigational agent. Clinical practice guidelines recommend using the same target dosing of therapies, as tolerated. However, with the increasing number of available therapies, clinicians face the challenge of simultaneously using several drugs, achieving target doses, and managing side effects that are often overlapping. Blood pressure, renal function, hyperkalaemia, and other factors may impede achieving target doses of all medications, leaving clinicians with dilemmas as to how to sequence and dose these various classes of drugs. The guideline-directed eligibility for certain drugs and devices requires stability on maximally tolerated doses of background therapies. However, significant variability exists in dosing achieved in clinical practice. We discuss the existing background data regarding the doses of heart failure medications in clinical trials and in practice, and provide recommendations on how to navigate this complex therapeutic decision-making.

Full Text

Duke Authors

Cited Authors

  • Marti, CN; Fonarow, GC; Anker, SD; Yancy, C; Vaduganathan, M; Greene, SJ; Ahmed, A; Januzzi, JL; Gheorghiade, M; Filippatos, G; Butler, J

Published Date

  • March 2019

Published In

Volume / Issue

  • 21 / 3

Start / End Page

  • 286 - 296

PubMed ID

  • 30537163

Pubmed Central ID

  • 30537163

Electronic International Standard Serial Number (EISSN)

  • 1879-0844

Digital Object Identifier (DOI)

  • 10.1002/ejhf.1351

Language

  • eng

Conference Location

  • England